A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)

Trial Profile

A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Ureteral-neoplasms; Urethral cancer
  • Focus Therapeutic Use
  • Acronyms NEXT
  • Most Recent Events

    • 20 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 06 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
    • 02 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top